The global macrolide drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Macrolides are a class of antibiotics that includes erythromycin, roxithromycin, azithromycin and clarithromycin and are used in the treatment of respiratory, skin, soft tissue, sexually transmitted, H. pylori and atypical mycobacterial infections. The major factor for the growth of the  market during the forecast period is the growing demand for antibiotics. 

Additionally, the market is also growing owing to the rising prevalence of bacterial skin infections along with supportive government policies and legislation. Moreover, North America held the largest share in the market in 2020 owing to the well-developed healthcare infrastructure, increased R&D activities by the pharmaceutical companies as well as rapid adoption of new along with better healthcare technologies.

Some major players in the market include GlaxoSmithKline plc, Novartis AG, and Pfizer Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in March 2018, Macrolide Pharmaceuticals announced that it received a CARB-X award of up to $6.8M to support the development of a novel fully synthetic, orally available macrolide antibiotic with Gram-negative activity, to treat serious infections including drug-resistant complicated urinary tract infections (cUTI).

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Drugs

o By Route of Administration

o By Infection

o By End-User

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- GlaxoSmithKline plc, Novartis AG, and Pfizer Inc., among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How players are addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Macrolide Drugs Market Report by Segment

By Drugs 

• Azithromycin

• Clarithromycin

• Erythromycin

• Fidaxomicin 

• Telithromycin

By Route of Administration 

• Oral 

• Parenteral

By Infection 

• Mycoplasma Pneumoniae

• Legionella SP

• Bordetella Pertussis

• Symptomatic Cat-Scratch Disease

• Bacillary angiomatosis

• Peliosishepatis

• Cerebral Toxoplasmosis 

• Uncomplicated Skin Infections

By End-User 

• Hospital

• Dermatology Clinic

• Ambulatory Center

• Research Laboratories

Global Macrolide Drugs Market Report by Region

North America

• United States

• Canada

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa